Every Form 4 that MacroGenics, Inc. (MGNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGNX filings page.
MACROGENICS INC (MGNX) reported that officer Jeffrey Stuart Peters, Senior VP, GC, and Secretary, sold 31,105 shares of common stock on 2026-08-19 in an open-market or private transaction. The sale, effected under a Rule 10b5-1 trading plan adopted on May 20, 2026, was executed in multiple trades at prices ranging from $4.12 to $4.24 per share, with a reported per-share price of $4.15. Following this transaction, Peters reported holding 0 shares of MacroGenics common stock directly.
MACROGENICS INC (MGNX) reported that Sr VP, Research & CSO Ezio Bonvini40,000 shares at $2.60 per share on 2026-08-17. This option exercise converted into 40,000 shares of Common Stock in an exercise-and-hold transaction. Following the transaction, Bonvini directly holds 185,799 shares of Common Stock and 88,000 Employee Stock Options with an exercise price of $2.60 per share expiring on 2035-02-07. Footnotes indicate a staggered vesting schedule for the option grant.
MACROGENICS INC director Federica F. O'Brien reported equity compensation and an option exercise. On May 18, 2026, 3,750 restricted stock units vested and were exercised into 3,750 shares of common stock, leaving her with 14,750 common shares directly owned.
On May 19, 2026, she received a grant of 3,750 new restricted stock units and a stock option for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. The option vests in monthly 1/12th increments, while the new RSUs vest one year from grant or the day prior to the next annual meeting, if earlier. These are compensation-related awards, not open-market purchases.
MACROGENICS INC director Scott Thomas Jackson reported equity awards and an RSU vesting. On May 19, 2026, he received a stock option for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. He was also granted 3,750 restricted stock units (RSUs), each representing one share of common stock and scheduled to vest one year after grant or the day before the next annual meeting, if earlier.
On May 18, 2026, 3,750 RSUs vested and were exercised into 3,750 shares of common stock. Following these transactions, Jackson directly holds 14,750 shares of common stock, plus the new 3,750 RSUs and the 22,000 stock options. These are compensation-related awards and an RSU-to-share conversion, not open‑market purchases or sales.
MACROGENICS INC director William K. Heiden reported routine equity compensation activity. On May 19, 2026, he was granted stock options for 22,000 shares of common stock with an exercise price of $4.52 per share, expiring on May 19, 2036. He also received a grant of 3,750 restricted stock units (RSUs) that will vest one year after the grant date or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, bringing his direct common stock holdings to 114,750 shares. These transactions reflect awards and an RSU vesting/exercise, with no open‑market purchases or sales.
MACROGENICS INC director Jay Philip Siegel exercised restricted stock units into common shares. On May 18, 2026, he converted 3,750 restricted stock units into 3,750 shares of common stock at a stated price of $0.00 per share.
The restricted stock units vested on May 18, 2026, one day before the company’s 2026 annual meeting of stockholders held on May 19, 2026. Following this exercise-and-hold transaction, Siegel directly owns 14,750 shares of MacroGenics common stock and no longer holds the vested RSUs as a separate derivative position.
MACROGENICS INC director Margaret Liu reported routine equity compensation activity. She received a stock option grant for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. She was also granted 3,750 restricted stock units, each representing one share of common stock, which will vest one year after the grant date or the day before the next annual meeting, if earlier. Separately, 3,750 previously granted RSUs vested on May 18, 2026 and were exercised into 3,750 shares of common stock, bringing her direct common stock holdings to 14,750 shares.
MACROGENICS INC director Meenu Chhabra reported routine equity compensation activity. On May 19, 2026, she received grants of 3,750 restricted stock units and 22,000 stock options with a conversion or exercise price of $4.5200 per share, both held directly. The options vest in monthly 1/12th increments beginning one month from the grant date, while the RSUs vest one year from grant or the day before the next annual meeting, if earlier.
On May 18, 2026, 3,750 RSUs vested and were exercised into 3,750 shares of common stock, increasing her directly held common stock to 14,750 shares. These transactions reflect compensation-related grants and an RSU vesting and conversion, with no open-market buys or sells reported.
MACROGENICS INC director Edward Hurwitz reported routine equity compensation activity and an option exercise. On May 19, 2026, he received stock options for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036.
He was also granted 3,750 restricted stock units (RSUs), each representing one share of common stock, which will vest one year after the grant date or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, leaving him with 47,824 common shares held directly after the transactions.
MACROGENICS INC director David C. Stump reported routine equity compensation and an option exercise. On May 18, 2026, 3,750 restricted stock units (RSUs) vested and were converted into 3,750 shares of common stock, and he held 14,750 common shares directly afterward. On May 19, 2026, he received a grant of stock options for 22,000 shares at an exercise price of $4.52 per share, expiring on May 19, 2036, plus a new award of 3,750 RSUs. The filing notes that RSUs vest around the company’s annual meetings and that the new options vest monthly in 1/12th increments beginning one month after grant.
MACROGENICS INC director Karen Jean Ferrante reported equity compensation transactions. On May 19, 2026, she received a stock option grant for 22,000 shares of common stock at an exercise price of $4.52 per share, expiring on May 19, 2036. She also received 3,750 restricted stock units (RSUs), each representing one future share of common stock, which vest one year after grant or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, increasing her direct common stock holdings to 14,750 shares.
MacroGenics Inc. director Scott Koenig received new equity awards. He was granted stock options for 22,000 shares of common stock with an exercise price of $4.52 per share, expiring in 2036.
Koenig was also granted 3,750 restricted stock units, each representing one share of common stock. The RSUs vest one year after the grant date, or the day before the next annual meeting if earlier. The options vest in monthly 1/12th increments starting one month after grant.
MacroGenics senior vice president and CSO Ezio Bonvini reported equity grants and related share activity. On February 12, 2026 he received 31,250 restricted stock units and options for 187,500 shares at $1.71 per share, expiring February 12, 2036. On February 15, 2026 16,665 RSUs converted into common stock and 6,433 shares were withheld at $1.71 for taxes. After these transactions he directly holds 145,799 common shares and 31,250 RSUs.
MacroGenics (MGNX) vice president Beth Ann Smith reported several equity compensation transactions. On February 12, 2026, she received a grant of 15,625 restricted stock units (RSUs) and 93,750 employee stock options with an exercise price of $1.71 per share.
On February 15, 2026, 1,095 RSUs converted into the same number of common shares, increasing her directly held common stock to 13,204 shares before tax settlement. To cover tax obligations, 423 common shares were withheld at $1.71 per share, leaving her with 12,781 common shares held directly after the transactions.
MacroGenics SVP and CFO James Karrels reported multiple equity compensation moves. On February 15, 2026, he exercised 14,999 restricted stock units, receiving the same number of common shares at an exercise price of $0. In a related tax-withholding transaction coded "F," 5,790 common shares were disposed of at $1.71 per share, leaving him with 206,037 common shares held directly.
Earlier, on February 12, 2026, he was granted an employee stock option for 150,000 shares at an exercise price of $1.71 per share, expiring on February 12, 2036. He also received a new grant of 25,000 restricted stock units, each RSU representing a right to one share, scheduled to vest 33% one year after grant and 33% each year thereafter.
MacroGenics executive Jeffrey Stuart Peters, Senior VP, General Counsel and Secretary, reported several equity compensation moves. On February 15, 2026, 13,332 restricted stock units were exercised into common shares, and 5,147 of those shares were withheld at $1.71 per share to cover tax obligations, leaving 31,105 common shares held directly.
Earlier, on February 12, 2026, Peters received a grant of 150,000 employee stock options with a $1.71 exercise price, expiring on February 12, 2036, and a separate grant of 25,000 restricted stock units. The RSUs are scheduled to vest in three equal annual installments, each representing the right to receive one share of MacroGenics common stock.
MacroGenics senior vice president Thomas Spitznagel reported multiple equity transactions in February 2026. On February 12, 2026, he received 25,000 restricted stock units and an employee stock option for 150,000 shares of common stock at an exercise price of $1.71 per share.
On February 15, 2026, he exercised 13,332 restricted stock units, converting them into the same number of common shares, and 5,520 shares were disposed of at $1.71 per share to cover taxes or exercise costs. After these transactions, he directly owned 38,543 common shares of MacroGenics.
MacroGenics Inc. President and CEO Eric Blasius Risser reported several equity compensation moves. On February 12, 2026, he received 100,000 restricted stock units and 595,000 employee stock options, each tied to future vesting and exercisability conditions described in the filing.
On February 15, 2026, he exercised 16,665 restricted stock units, receiving the same number of common shares, and then disposed of 6,433 shares at $1.71 per share to cover tax obligations. After these transactions he directly owned 77,169 common shares of MacroGenics.
MacroGenics director Scott Koenig reported an RSU conversion into common stock. On February 15, 2026, he exercised restricted stock units and acquired 21,165 shares of MacroGenics common stock at a stated price of $0 per share, increasing his directly held position to 867,240 shares.
The RSUs were part of a 127,000-unit grant awarded on February 15, 2023. According to the disclosure, 84,670 units had vested before his separation from the company, and 21,165 additional units vested on August 13, 2025 under his Separation Agreement, with each RSU representing one share of common stock.
MacroGenics director Scott Koenig converted 15,831 restricted stock units into an equal number of MacroGenics common shares on February 8, 2026, at an exercise price of $0 per share. After this conversion, he directly owned 846,075 shares of common stock and 15,832 RSUs.
The RSUs come from a 95,000-unit grant on February 8, 2024. One-third vested after one year, and half of the remaining units vested under a Separation Agreement on August 13, 2025. The rest vest in two equal annual installments on the grant anniversary.
MacroGenics, Inc. senior vice president Thomas Spitznagel reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,001 and 8,999 shares of common stock, respectively, on a one-for-one basis. On each date, 2,485 and 3,186 shares were withheld at $1.81 per share to cover taxes. After these transactions, Spitznagel directly owned 30,731 shares of MacroGenics common stock.
MacroGenics VP, Controller & Treasurer Beth Ann Smith reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On February 7, 2026, 2,617 RSUs converted into 2,617 shares of common stock at an exercise price of $0, with 1,011 shares of common stock withheld at $1.81 per share, leaving 11,138 shares directly owned afterward. On February 8, 2026, a further 1,583 RSUs converted into 1,583 shares of common stock at $0, with 612 shares withheld at $1.81 per share, resulting in 12,109 common shares directly owned. RSUs convert into company stock on a one-for-one basis, and remaining RSU balances after these transactions were 5,233 and 1,584 units for the two respective grants.
MacroGenics (MGNX) President and CEO Eric Blasius Risser reported multiple equity award transactions in early February 2026. On February 7, 2026, 6,668 restricted stock units (RSUs) converted on a one-for-one basis into common stock, increasing his direct holdings to 62,657 shares before a 2,575-share disposition at $1.81 per share, leaving 60,082 shares.
On February 8, 2026, a further 11,166 RSUs converted into common stock, taking his direct common stock position to 71,248 shares before a 4,311-share disposition at $1.81 per share, resulting in 66,937 common shares directly owned. Following these transactions, he held 13,332 RSUs from a February 7, 2025 grant of 20,000 units and 11,166 RSUs from a February 8, 2024 grant of 33,500 units, each vesting in three equal annual installments.
MacroGenics, Inc. insider activity: Senior VP, General Counsel and Secretary Jeffrey Stuart Peters reported routine equity compensation events. On February 7 and 8, 2026, portions of previously granted restricted stock units vested and were converted into common stock on a one-for-one basis.
On those dates, a total of 6,001 and 8,999 common shares, respectively, were acquired upon RSU conversion at an exercise price of $0. In connection with these vestings, 2,317 and 3,474 shares of common stock were withheld at $1.81 per share to satisfy tax obligations, coded as transaction type “F.”
Following the reported transactions, Peters directly held 22,920 shares of MacroGenics common stock. He also continued to hold derivative positions in restricted stock units from earlier grants, which were originally 18,000 units granted on February 7, 2025 and 27,000 units granted on February 8, 2024, each vesting in three equal annual installments.
MacroGenics SVP and CFO James Karrels reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,334 and 9,999 shares of common stock, respectively, on a one-for-one basis. In connection with these vestings, 2,446 and 3,860 shares of common stock were withheld at $1.81 per share to cover tax obligations.
After these transactions, Karrels beneficially owned 196,828 shares of MacroGenics common stock, held directly and jointly with his wife, plus 12,666 and 9,999 remaining restricted stock units from prior grants that continue to vest over time.
MacroGenics Inc. insider activity: Sr VP, Research & CSO Ezio Bonvini reported routine equity transactions on February 7 and 8, 2026 involving restricted stock units (RSUs) and common stock of MacroGenics Inc. (MGNX).
On February 7, RSUs converting on a one-for-one basis were exercised for 7,001 shares of common stock, increasing his directly held common stock to 131,415 shares, while 2,703 shares were withheld at a price of $1.81 per share, leaving 128,712 shares directly owned. On February 8, an additional 11,166 RSUs were exercised into common stock, bringing direct common stock holdings to 139,878 shares before 4,311 shares were withheld at $1.81 per share, resulting in 135,567 directly owned common shares.
Following these transactions, Bonvini also held 13,999 RSUs from a February 7, 2025 grant of 21,000 RSUs vesting in three equal installments and 11,166 RSUs from a February 8, 2024 grant of 33,500 RSUs, also vesting in three equal installments beginning on the first anniversary of each grant date.